|
Market Cap (5-Jul) $86,511,600 (718th) |
Close (30-Jun) $0.63 |
Volume (30-Jun) 55,179 |
Shortsold (19-Jun) 190,561 (0.07%) (455th) |
|
52w High $0.57 |
52w Low $0.275 |
P/E - |
EPS -0.09 |
RCE released this announcement to the ASX on 1 August 2022, 9:15. The announcement is marked as price sensitive, and is 8 page(s) in length and 0.92MB in size.
You can view all announcements from RCE and see how they appear on a price chart on the announcements page.
At the date of this announcement, RCE was 0.079% short sold according to ASIC data. It was ranked the 509th most shorted stock on the ASX. It is now ranked as the 455th most shorted stock on the ASX with 0.066% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from RCE | |
|---|---|
| Ethics Approval for Phase I/II UTI Trial Expansion | 29 June 2023, 13:49 |
| Change of Director's Interest Notice - J Graham | 26 June 2023, 15:58 |
| DFI Clinical Trial Outpatient Nurses Appointed | 29 May 2023, 10:54 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 1 August 2022, 9:15 |
| Corporate Presentation - Aussie Equities Day 2022 | 28 July 2022, 11:24 |
| Dr Philip Sutton - V.P. of Translational Sciences | 11 July 2022, 10:16 |
| Phase I Positive Safety Data - 4000mg Complete | 21 June 2022, 10:40 |
You must be logged in to post a reply.
Recce Pharmaceuticals Ltd 